


Cell Host & Microbe

Inducible Germline IgMs Bridge Trypanosome Lytic Factor Assembly and Parasite Recognition

Graphical Abstract



Authors

Joseph Verdi, Ronnie Zipkin, Elani Hillman, ..., Nina Papavasiliou, Jeremy Sternberg, Jayne Raper

Correspondence

raper@genectr.hunter.cuny.edu

In Brief

Verdi, Zipkin et al. show that polyreactive germline IgMs, elicited during infection by African trypanosomes, enhance the innate immune functions of plasma trypanosome lytic factors via recognizing and potentially bridging factor component HPR and parasite surface proteins, including VSG.

Highlights

- TLF2 biogenesis in healthy individuals is driven by germline IgM interaction with HPR
- IgM levels and TLF2 formation increase in trypanosome-infected patients
- IgMs raised in trypanosome infection and TLF2-IgMs recognize HPR and parasite VSG
- A murine model generates TLF2 in $AID^{-/-}$ mice by germline IgM recognition of human HPR



Article

Inducible Germline IgMs Bridge Trypanosome Lytic Factor Assembly and Parasite Recognition

Joseph Verdi,^{1,2,4,7} Ronnie Zipkin,^{1,3,6,7} Elani Hillman,¹ Rahel A. Gertsch,¹ Sarah J. Pangburn,^{1,2} Russell Thomson,¹ Nina Papavasiliou,⁴ Jeremy Sternberg,⁵ and Jayne Raper^{1,2,3,8,*}

¹Department of Biological Sciences, Hunter College at City University of New York, New York, NY 10065, USA

²Department of Biology, The Graduate Center at City University of New York, New York, NY 10016, USA

³Division of Parasitology, Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA

⁴Division of Immune Diversity, German Cancer Research Center, Heidelberg, Germany

⁵Institute of Biological and Environmental Sciences, University of Aberdeen, Aberdeen, UK

⁶Department of Biomedical Data Science, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03756, USA

⁷These authors contributed equally

⁸Lead Contact

*Correspondence: raper@genectr.hunter.cuny.edu

<https://doi.org/10.1016/j.chom.2020.04.012>

SUMMARY

Trypanosomiasis is a devastating neglected tropical disease affecting livestock and humans. Humans are susceptible to two *Trypanosoma brucei* subspecies but protected from other trypanosomes by circulating high-density lipoprotein (HDL) complexes called trypanosome lytic factors (TLFs) 1 and 2. TLFs contain apolipoprotein L-1 contributing to lysis and haptoglobin-related protein (HPR), which can function as a ligand for a parasite receptor. TLF2 also uniquely contains non-covalently associated immunoglobulin M (IgM) antibodies, the role and origin of which remain unclear. Here, we show that these TLF2-associated IgMs interact with both HPR and alternate trypanosome surface proteins, including variant surface glycoprotein, likely facilitating complex biogenesis and TLF uptake into parasites. TLF2-IgMs are germline antibodies that, while present at basal concentrations in healthy individuals, are elicited by trypanosome infection in both murine models and human sleeping sickness patients. These data suggest that poly- and self-reactive germline antibodies such as TLF2-associated IgMs play a role in antimicrobial immunity.

INTRODUCTION

Humans, gorillas, and certain old-world monkeys are immune to infection by the fly-transmitted protozoan *Trypanosoma brucei*. Immunity to *T. b. brucei* is due to a primate-specific innate defense mechanism mediated by a subset of circulating high-density lipoprotein (HDL) complexes called trypanosome lytic factors (TLFs) 1 and 2 (Rifkin, 1978; Hajduk et al., 1989; Raper et al., 1999). Humans can be infected by *T. b. rhodesiense* and *T. b. gambiense*, both of which have evolved mechanisms to block TLF-mediated innate immunity (Vanhamme et al., 2003; Stephens and Hajduk, 2011; Uzureau et al., 2013). Both TLFs contain the primate-specific ion channel-forming protein apolipoprotein L-1 (APOL1), which lyses the parasites by forming cation-selective pH-gated channels in the parasite membranes after endocytosis (Thomson and Finkelstein, 2015). To form open channels, APOL1 requires an initial membrane insertion step dependent on acidification in the endocytic compartments, followed by a neutralization step that likely occurs at the plasma membrane after endocytic recycling (Thomson and Finkelstein, 2015). Both TLFs also contain the primate-specific hemoglobin (HB)-binding protein haptoglobin (HP)-related protein (HPR). HPR-HB complexes are endocytosed after binding the trypano-

some haptoglobin-hemoglobin receptor (HPHBR) (Vanhollebeke et al., 2008), though this interaction can be inhibited by physiological concentrations of HP-HB complexes (Raper et al., 1996). Receptor-mediated endocytosis of TLF1 is dependent on the HPHBR; however, TLF2 endocytosis cannot be inhibited by HP-HB complexes and is therefore independent of the HPHBR (Raper et al., 1996). These biochemical experiments have also been supported by reverse genetics, where knock-down of the HPHBR increased *T. b. brucei* resistance to TLF1 by 10,000-fold, whereas resistance to TLF2 was increased by only 500–1,000-fold (Bullard et al., 2012). While we cannot rule out the possibility of an interaction between TLF2 and the HPHBR, the data suggest that TLF2 has an alternative endocytosis mechanism and that TLF2 is the main lytic factor in normal human serum, as TLF1 activity is inhibited by physiologic HP-HB concentrations.

TLF2 is distinguished from TLF1 by the association of immunoglobulin M (IgM) antibodies with the TLF2 complex that may play a role in TLF2 endocytosis (Raper et al., 1999). Pentameric IgM antibodies typically bind with relatively low affinity and high avidity to their cognate antigen. These low-affinity TLF2-associated IgMs (TLF2-IgMs) are polyclonal and interact with the complex non-covalently (Raper et al., 1999). The exact stoichiometry



is unclear, however, based on the sizes of the TLF1 (~500 kDa) and TLF2 (~1,400 kDa) complexes, we hypothesize that each TLF2 is comprised one TLF1 (~500 kDa) and one IgM (950 kDa). All healthy humans produce IgM antibodies as the first humoral response to infection. All healthy humans also produce IgM antibodies that do not undergo affinity maturation called natural or germline antibodies (Siloși et al., 2016). Germline antibodies are often associated with the recognition of self-antigens, such as apoptotic debris and other damage-associated molecular patterns (DAMPs), and do not require an infectious stimulus to be produced. TLF2-IgMs are present in every human plasma sample screened thus far, suggesting that they are germline antibodies that could simultaneously interact with both the TLF complex and with ubiquitous antigens.

Trypanosome parasites proliferate extracellularly in the bloodstream and interstitial spaces and are able to evade antibody-mediated adaptive responses by antigenic variation of their surface coat (Mugnier et al., 2015). Trypanosomes monoallelically express only one of 2,000 alleles of the dominant coat protein, the variant surface glycoprotein (VSG). Mueller et al. clearly demonstrated that anti-VSG antibody specificities preexist in humans and mice that have never been exposed to the trypanosome (Müller et al., 1996). These germline anti-VSG antibodies also cross-react with—and are possibly raised against—DAMPs (Müller et al., 1996). Given that many germline antibodies target trypanosome surface proteins, and many germline antibodies are polyreactive, we hypothesized that TLF2-IgMs are germline antibodies that can interact with multiple trypanosome antigens with weak affinity. We report here an investigation into the role that TLF2-IgMs play in trypanosome immunity. We find that TLF2-IgMs interact with the TLF protein HPR and many trypanosome proteins, thus offering a route for TLF2 uptake and thereby providing primates with a second mechanism of targeting APOL1 for endocytic uptake by the parasite—one independent of the HPHBR.

RESULTS

Coexpression of Human HPR and APOL1 Drives TLF2 Formation in AID-Null Mice

To biochemically query specific TLF component interactions, we designed a modular system that allows us to purify and assemble various TLF components from animal serum. We had previously reconstituted TLF1 in various mouse strains by transiently expressing the TLF proteins HPR and APOL1 by hydrodynamic gene delivery (HGD) (Kovacsics and Raper, 2014). While HGD has proven a useful tool for the study of TLF1, TLF2 formation has never been reported in any murine models. We hypothesize that the concentration of IgM antibodies available for TLF2 formation is too low in routinely used murine models to produce detectable levels of TLF2 after HGD. Since TLF2-IgMs are present in all analyzed human plasma samples, we hypothesized that TLF2-IgMs are germline antibodies. We therefore used HGD to express *HPR* and *APOL1* in mice that produce germline antibodies at higher concentrations than wild-type mice due to knockout of activation-induced cytidine deaminase (AID), which mediates somatic hypermutation and class switch recombination (Robbiani et al., 2008). *AID*^{-/-} mice can only produce immunoglobulins of the M class, many of

which are auto-reactive species. We then analyzed plasma from mice transfected by HGD by size exclusion chromatography to separate TLF2 (~1,400 kDa) and TLF1 (~500 kDa). These columns are packed with a porous matrix resin that separates molecules based on differences in size, with the largest molecules eluting first (more information can be accessed at <https://www.gelifesciences.com/en/us/solutions/protein-research/knowledge-center/protein-purification-methods/size-exclusion-chromatography#size-exclusion>). Size exclusion chromatography of plasma from mice expressing human *APOL1* and *HPR* revealed both TLF2-like and TLF1-like HPR- and APOL1-containing complexes (Figure 1B), though the TLF2-like complexes had smaller hydrodynamic radii than human TLF2 (Raper et al., 1999). TLF2 and TLF1 can also be separated by non-denaturing polyacrylamide (Weckerle et al., 2016) or agarose (Figure S1) gel electrophoresis, which we used to characterize murine TLF2 complexes. Both the concentrated TLF2-containing fractions (lane 1) and the originating unfractionated plasma (lane 3) had APOL1 in the TLF2 range (Figure 1C), and APOL1 was detected in the TLF1 range only in whole murine plasma (lane 3) (Figure 1C). The TLF2-like complexes in mL 67 and 67.5 of Figure 1A were immunoprecipitated (IP) using HPR as the target antigen, which precipitated both APOL1 and IgM (Figure 1D), indicating that all three components were present in the same complex. Therefore, using HGD delivery in *AID*^{-/-} animals we assemble TLF2 in mouse plasma.

TLF2-IgMs Interact with HPR

As HGD-generated TLF2 contains germline IgM from mouse plasma, we sought to evaluate any interactions with TLF components: human HPR, human APOL1, and murine apolipoprotein A-I (APOA-I), the structural protein of HDLs. Germline antibodies often interact with low affinity to self-antigens, so we first asked whether TLF2-IgM was polyreactive and anti-self. For that, we used purified human TLF2 (Figures S3A–S3C) to probe membranes in far-western blot experiments and observed that TLF2-IgMs interact with various components of human and trypanosome cell lysates (Figure S3). To then understand how such a polyreactive component would interact with the TLF proteins, we used our HGD mouse model to generate components of TLF and assess their individual interactions with IgM. To analyze the interaction between TLF2-IgM and native HDLs, we expressed either *HPR* or *APOL1* in *AID*^{-/-} mice by HGD and analyzed the mouse plasma by size exclusion chromatography. Expression of *HPR* in *AID*^{-/-} mice (Figure 2A) resulted in the formation of an HPR-HDL-IgM immunocomplex that co-migrated with murine APOA-I, the structural protein of HDLs, and eluted from the column prior to the bulk of the murine HDL complexes (i.e., shifted the migration pattern of APOA-I, Figure 2B). The HPR-HDL-IgM complex was validated by Co-IP (Figure 2C). Expression of *APOL1* in *AID*^{-/-} mice (Figure 2D) did not produce a detectable immunocomplex, and all of the APOL1 co-migrated with the bulk of the murine HDL and did not shift the migration pattern of APOA-I (Figure 2E). Transfection by HGD did not significantly alter the total protein distribution in murine plasma (Figure S4), and HGD of saline alone did not shift the migration pattern of APOA-I (Figure 2F). These findings were validated through far-western experiments in which we used human TLF2-IgM to probe APOL1 HDLs or HPR HDLs derived from




Figure 1. Coexpression of Human *APOL1* and *HPR* Results in TLF2 Formation in *AID*^{-/-} Mice

(A) Schematic representation of the vector used to transiently induce TLF gene expression in *AID*^{-/-} mice. The ubiquitin promoter (pink arrow) drives expression of both mammalian transgenes (HuAPOL1: green, HuHPR: orange) in order to induce gene expression in any cell type. A beta-globin intron (purple) and an SV40 polyadenylation signal (teal) flank all transgenes to increase mRNA stability. Beta-lactamase (yellow) is used for antibiotic selection during bacterial propagation in *E. coli* via an origin of replication (peach circle).

(B) Pooled plasma was obtained from two mice that were transiently expressing *APOL1* and *HPR*. The plasma (0.75 mL) was then separated by size on a Superose 6 size exclusion column (1.5 by 60 cm), and the fractions were analyzed by western blot. The earliest eluting TLF-containing fractions ($\geq 1,000$ kDa) that coeluted with IgM were designated TLF2, while the TLF-containing fractions eluting after mL 69 were designated TLF1 (≤ 500 kDa).

(C) Anti-APOL1 western blot of pooled mL 67 and 67.5 (TLF2) from A, transfected murine plasma (TLF1 and TLF2), and normal human plasma (TLF1 and TLF2) after separation by native agarose gel electrophoresis. Lane 2 contains ferritin and apoferritin (Pharmacia) that migrates the same distance as human bulk HDL (denoted by **) that was used as a reference to compare relative migration distances across gels. A component of the marker interacts non-specifically with the secondary antibody at (*).

(D) Western blot analysis (IgM and APOL1) of a co-immunoprecipitation using an antibody recognizing human HPR (Sigma H6395) of pooled mL 67 and 67.5 from (A).

transfected mice (Figure 2G). We found that TLF2-IgMs interacted with a human HPR-sized protein, but not human APOL1 (Figure 2G). Unsurprisingly, due to the polyclonal IgM component, TLF2-IgMs can interact with many unidentified components of human and murine plasma, though the strongest detectable interaction was with the 45-kDa human HPR protein (Figure 2Hd), which is associated with TLF *in vivo*. We conclude that an interaction between the TLF2-IgMs and HPR-bound HDL is required for TLF2 assembly *in vivo*, but that TLF2-IgMs can also interact with many other self-antigens with low affinity.

TLF2-IgMs Purified from Human Plasma Interact with Trypanosome Proteins

While both TLF1 and TLF2 have been identified as trypanosome lytic factors, previous work has demonstrated that TLF2 is far more relevant in the context of human disease (Raper et al., 1996). Given that TLF1 and 2 differ by a single component (IgM) and that the trypanosome surface is densely coated with VSG (a target for IgM), we and others (Vanhollebeke and Pays, 2010) hypothesized that human TLF2-IgMs could facilitate TLF2 uptake by trypanosomes via low-affinity interactions with trypanosome surface antigens. To investigate this *in vitro*, we

first probed total trypanosome lysates with human TLF2-IgMs under native (dot blot) and denaturing (SDS-PAGE) conditions and observed interactions between TLF2-IgMs and many trypanosome antigens (Figures 3A and 3B). Since the dominant trypanosome surface antigen, representing 10%–20% of the cell's total protein and 99% of the cell surfeome (Shimogawa et al., 2015), is the ~60 kDa GPI-anchored VSG, we then investigated whether TLF2-IgMs could interact directly with VSG. To do so, we first isolated the GPI-anchored trypanosome proteins in their soluble form from three clones, each expressing a different VSG, by hypotonic lysis to enrich for VSG, as described previously (Cardoso De Almeida and Turner, 1983) (Figure S5). Under native conditions, TLF2-IgMs interacted most strongly with the VSG3 preparation, while lower-affinity interactions were observed between TLF2-IgMs and VSGs 2 and 13 (Figure 3C). VSGs have been classified into multiple groups based on the distribution of cysteines throughout the amino acid sequence (Carrington et al., 1991). Both VSG2 and 13 are class A VSGs, while VSG3 is a class B VSG that is highly structurally divergent (Pinger et al., 2018), suggesting that TLF2-IgMs may have some structural specificity, though this will require further investigation. Taken together, these data reveal that the




Figure 2. TLF2-IgMs Interact with HPR

(A) Schematic representation of the vector used to transiently induce *HPR* expression in *AID*^{-/-} mice. The labeling is analogous to the labeling in Figure 1A. (B) Western blots of size fractionated human *HPR* expressing *AID*^{-/-} murine plasma (Superose 6). Milliliters containing IgM-HPR-HDL complexes are marked by “immunocomplex” and milliliters containing HPR-HDL that does not co-migrate with IgM are marked by “HPR-HDL.” The HPR western blot was transferred from a non-reduced PAG, which efficiently separates HPR (45 kDa) from HP (90 kDa). The IgM and APOA-I were transferred from a reduced PAG to follow the IgM heavy chain (63 kDa) and APOA-I (28 kDa) (HP and HPR beta chains co-migrate on reducing gels). (C) Western blot analysis (IgM) of a co-immunoprecipitation of pooled milliliters 66 and 66.5 from A using an antibody recognizing human HPR (Sigma H6395). (D) Schematic representation of the vector used to transiently induce *APOL1* expression in *AID*^{-/-} mice. The labeling is analogous to the labeling in Figure 1A. (E) Western blots of size fractionated human *APOL1* expressing *AID*^{-/-} murine plasma (Superose 6). (F) Western blot of size fractionated untransfected *AID*^{-/-} murine plasma (Superose 6).

(legend continued on next page)




Figure 3. TLF2-IgMs Purified from Human Plasma Interact with Trypanosome Proteins

(A) Native dot blot using TLF2-IgMs as bait and non-denatured trypanosome lysates, human IgM, or human HP as prey.

(B) Far-western blot using TLF2-IgMs as bait and an SDS-PAGE denatured trypanosome lysate preparation as prey.

(C) Native dot blot using TLF2-IgMs as bait and murine HDL after mock transfection with saline, murine HDL after transfection with human *HPR*, murine HDL after transfection with human *APOL1*, VSG2, 3, and 13 preparations, or non-denatured trypanosome lysate as prey. We estimate that by this technique, TLF2-IgMs have an approximately 5–6-fold higher affinity for VSG3 than that for VSGs 2 or 13.

polyclonal IgM component of TLF2, as it is present in the plasma of uninfected humans, can interact with VSG and other trypanosome proteins. Various kinetic experiments investigating the rate at which parasites are lysed by TLFs strongly suggest that TLF2 uptake occurs more rapidly than fluid phase endocytosis, despite the lack of an identified receptor (Vanhollebeke et al., 2007). We hypothesize that TLF2-bound VSG is internalized by the molecular sail mechanism by which antibody-bound VSGs are rapidly endocytosed (Engstler et al., 2007).

TLF2-IgM Production Increases Substantially upon Trypanosome Infection in Wild-Type Mice

Given that human TLF2-IgMs interact with trypanosome antigens, we hypothesized that trypanosome infection could increase the production of IgMs that could interact with TLF2 in wild-type mice. Swiss Webster and *AJ* mice were infected with *T. b. brucei* for 4 days prior to treatment with diminazene aceturate to cure the infection. We then used HGD to express the TLF genes in the mice 12 days post-infection and analyzed the plasma by size exclusion chromatography at 14 days post infection (two days post-HGD with *HPR* and *APOL1*), during the peak of the IgM response to trypanosomes (Baral et al., 2007). Sizing the plasma revealed that the *APOL1* protein migrated exclusively with the bulk HDL and did not shift the migration pattern of APOA-I in uninfected mice (Figure 4A), whereas a significant portion of the *APOL1* shifted to the fractions containing larger complexes in the infected and cured

mice and co-migrated with bulk IgM (Figure 4A). To further investigate whether the IgM elicited by trypanosome infection in mice is TLF2-IgM, we used plasma from another trypanosome-infected mouse to screen for potential infection-derived murine IgM interactions with human TLF proteins. Trypanosome infection-derived IgMs interacted with human *HPR* and another unidentified murine HDL protein (Figure 4Bc), whereas IgM from uninfected mice does not recognize any HDL or TLF proteins (Figure 4Bb). This may indicate that trypanosome infection increases the circulating TLF2-IgM pool by increasing the circulating amount of IgMs that can interact with the TLF protein *HPR*. As trypanosome infection has been shown to elicit a strong IgM response in mice (25), it is possible that a portion of these represents a unique population of TLF2-IgMs capable of being recruited into TLF2 complexes.

Trypanosome Infection Increases TLF2-IgM Production in Sleeping Sickness Patients

The production of TLF2-IgMs in mice was likely due to an increased concentration of circulating germline IgMs that can interact with TLF. This suggests that there is a threshold of (or binding quality of) germline IgM concentration that is required in order to form detectable quantities of TLF2. In humans, TLF2-IgMs are present regardless of infection status. We investigated whether trypanosome infection, akin to the mice, would also increase the concentration of circulating TLF2-IgMs in sleeping sickness patients (Table 1). We found that trypanosome

(G) Far-western blot using TLF2 as the bait protein to detect prey proteins in murine plasma, murine HDL, murine HDL after transfection with human *HPR*, and murine HDL after transfection with human *APOL1*. The band in lane 3 at ~45 kDa likely corresponds to human *HPR* as denoted by the “huHPR” caption between the 35 and 55 kDa MW markers.

(H) Far-western blot showing the interactions between TLF2-IgMs (bait) and prey proteins in human plasma, bovine plasma, murine plasma, murine HDL after mock transfection with saline, murine HDL after transfection with human *HPR*, and purified human TLF1. Four identical membranes were prepared and probed as indicated. (Ha) was probed with an anti-HP antibody that recognizes both HP (high molecular weight bands) and *HPR* (~45 kDa). (Hb) was probed with a secondary antibody that recognizes human IgM including the IgM component of TLF2. (Hc) was probed with human IgM, followed by the secondary antibody that recognizes human IgM. (Hd) was probed with purified human TLF2, followed by the secondary antibody that recognizes human IgM. (Hc) was probed with pooled human IgM at a concentration equimolar to that which was used in (Hd). The arrowhead marks the 45-kDa human *HPR* protein, present in lanes 1, 5, and 6 of (Ha) and (Hd).




Figure 4. TLF2-IgM Production Increases Substantially upon Trypanosome Infection in Wild-Type Mice

(A) Anti-APOL1 western blots of size fractionated (Superdex 200 10/300) murine plasma samples expressing human *APOL1* and *HPR*. Top panel: A/J mouse infected with and cured of *T. b. brucei*. Middle panel: Swiss-Webster mouse infected with and cured of *T. b. brucei*. Bottom panel: uninfected Swiss-Webster mouse.

(B) Western blot showing the interaction between murine IgMs and SDS-PAGE separated proteins from human plasma, bovine plasma, murine plasma after mock transfection with saline, murine HDL after mock transfection with saline, and murine HDL after transfection with human *HPR*. Samples were probed with non-specific murine IgM (Ba), healthy murine plasma (Bb), and murine plasma from a *T. b. brucei* AnTat 1.1-infected Swiss-Webster mouse (Bc). The amount of non-specific IgM used in (Ba) was at an equimolar concentration relative to (Bc) as determined by ELISA. The bands present in lane 1 cannot be identified by this technique. The bands present in lane 3 of each blot are likely murine IgM. The bands marked by two arrowheads below *HPR* (marked by one arrowhead) in lanes 4 and 5 could correspond to murine APOA-I based on the molecular weight of the protein, although this is speculation.

infection led to a roughly 50-fold increase in circulating total IgM concentration (Figure 5A). We then analyzed the ratio of TLF2-associated APOL1 to TLF1-associated APOL1 and found that the ratio was substantially shifted toward TLF2 in infected individuals, while uninfected African or American control samples contained >95% TLF1 (Figures 5B and S6). This suggests that, while only a small fraction of the circulating IgMs in healthy individuals are TLF2-IgMs, trypanosome infection increases that fraction by increasing the abundance of polyclonal trypanosome-reactive IgMs.

One hallmark of trypanosome infection is an increase in circulating type II interferons (Wu et al., 2017), which we confirmed in the study of this cohort of patient samples (Figure 5C). Type II interferon signaling is known to upregulate *APOL1* mRNA expression in cell culture (Zhaorigetu et al., 2008), and human *T. b. gambiense* infection stimulates *APOL1* RNA upregulation (Iboudo et al., 2012), suggesting that total APOL1 and thus

TLF levels increase during trypanosome infection. This was demonstrably not the case, as we instead found that trypanosome infection did not significantly change the circulating APOL1 concentration relative to uninfected controls (Figure 5D). The regulation of circulating APOL1 concentration is likely multifactorial, and therefore we investigated whether the total amount of HDL was affected by trypanosome infection, as it is reduced during many other infections (Feingold and Grunfeld, 2000). Indeed, the circulating HDL concentration (APOA-I protein) was reduced 5- to 6-fold in infected individuals relative to healthy controls (Figure 5E). These data reveal that trypanosome infection does not change the total amount of circulating TLF, defined by the total amount of circulating APOL1, but that it leads to a redistribution of the available APOL1 into TLF2 complexes by increasing the circulating levels of TLF2-IgMs.

Taking all of these data together, we interpret that TLF1 and IgM exist in equilibrium with TLF2 *in vivo*, and that the circulating concentration of TLF2 is entirely dependent on the amount of circulating TLF2-IgMs at any given time. Consistent with this hypothesis, purified human TLF2 samples reproducibly contain TLF1 (Figure S1), likely due to a depletion of TLF2-IgMs from the sample during the stringent purification strategy. These data reveal that the interaction between germline IgMs and TLF1 is a low-affinity interaction that forms TLF2, and that this interaction likely plays a significant role in trypanosome immunity.

DISCUSSION

Both TLF1 and TLF2 are trypanolytic protein complexes that harbor most of the same components, with the exception of the IgMs associated with TLF2 (Raper et al., 1999). Here, we have investigated the properties of the TLF2-IgMs and the nature of their association with TLF. We hypothesize that TLF1 and TLF2 are the same protein complex that is IgM free as TLF1, IgM associated as TLF2, and that TLF and IgM exist in equilibrium. The TLF-associated IgMs are likely germline antibodies, given that all tested humans have detectable levels of TLF2 (Figure 5B) and *AID*^{-/-} mice, which express high levels of germline IgM, produce TLF2-IgMs (Figures 1 and 2). This hypothesis also stipulates that while the circulating concentration of TLF2-IgMs is high enough to mediate TLF2 formation in trypanosome-naïve humans, an increase in the production of TLF2-IgMs would subsequently lead to an increase in the circulating levels of TLF2. We have indeed observed that trypanosome-infected mice (Figure 4A) and humans (Figure 5B) produce more TLF2 than their uninfected counterparts. In the context of a trypanosome infection, it is also possible that some of the antigen adapted IgMs produced by somatically hypermutated B cells could associate with TLF to form TLF2. However, we hypothesize that a significant portion of the TLF-IgM pool is of germline origin.

The data presented here indicate that TLF2-IgMs interact with the HPR component of TLF1 in order to form TLF2 (Figure 2). HPR is a glycoprotein bound to HDL complexes via a retained signal peptide. This directed association ensures that the receptor-binding face of HPR is consistently exposed to the external environment, thereby increasing the probability of binding the trypanosome HP-HB receptor resulting in receptor-mediated

Table 1. Details of Patients and Controls

	Patients (n = 21)	Controls (n = 19)
Male:female	10:11	9:10
Median age (range)	25 (6–65)	35 (8–59)
Early:late stage	4:17	N/A

Staging criteria and treatment regimens were fully described by [MacLean et al., 2010](#). By definition, early cases are in the hemolymphatic stage of infection, while late cases are in the meningoencephalitic stage.

uptake. TLF2 is taken up by trypanosomes independently of the HPHBR. We propose that the source of TLF2's HPHBR independence is due to the 950-kDa IgM antibody interacting with HPR and therefore blocking the interaction with the receptor. This HPR-IgM interaction is non-covalent and of low affinity, such that the IgM may dissociate at any time and reveal the receptor-binding domain, permitting HPHBR-mediated uptake. [Bullard et al.](#), using RNA interference, observed that HPHBR depletion resulted in a 10,000-fold increase in the amount of TLF1 required to lyse *T. b. brucei* parasites, while only 100-fold more TLF2 was required ([Bullard et al., 2012](#)). This suggested that TLF2 is at least partially dependent on the HPHBR for uptake. However, this model of TLF-IgM equilibrium may suggest that a fraction of the TLF in those purified TLF2 samples had disassociated from IgM, thereby forming TLF1, leading to HPHBR-mediated uptake. This is supported by our observation that purified TLF2 samples invariably contain free “dissociated” TLF1 ([Figure S1](#)).

TLF2-IgMs are particularly promiscuous antibodies that interact with many self ([Figures 2 and S3](#)) and non-self-antigens ([Figures 3B and 3C](#)). This remarkable polyreactivity is a classic characteristic of germline IgM antibodies. We hypothesize that the TLF2-specific trypanosome uptake pathway may involve this polyreactive property of TLF2-IgMs, whereby the decavalent IgMs could interact with both the TLF and the surface of the parasite simultaneously. Trypanosomes endocytose antibody-bound VSGs within 2 min of antibody binding in order to evade antibody-mediated immunity ([Engstler et al., 2007](#)). We therefore hypothesize that TLF2-bound VSG would lead to TLF-associated APOL1 uptake by this same mechanism. A TLF2 uptake mechanism that depends on anti-VSG germline antibodies is consistent with work from [Mueller et al.](#), who revealed that auto-reactive IgMs in humans and other mammals recognize VSG proteins from various trypanosome isolates ([Müller et al., 1996](#)). In fact, some of the murine antibodies analyzed by [Mueller et al.](#) were derived from germ-free mice, thereby formally revealing that foreign antigen stimulus-independent systems produce anti-VSG IgMs. VSG is not the sole potential TLF2-IgM target epitope, as TLF2-IgMs can interact with a wide range of trypanosome antigens ([Figure 3B](#)). However, the fact that VSG exists in a roughly 10,000-fold molar excess relative to all other trypanosome surface proteins leads us to hypothesize that it is the most relevant surface protein with regard to TLF2 uptake. Under this assumption, it is possible that trypanosome infection-elicited TLF2-IgMs may afford TLFs with adaptive-like targeting potential by preferentially recognizing particular infection-specific VSG classes or variants.

Having two non-redundant mechanisms of APOL1 delivery to invading trypanosomes provides an immunological advantage.

In normal human serum, although TLF2 uptake is unabated, TLF1-mediated APOL1 uptake is effectively inhibited by the physiological levels of circulating HP ([Raper et al., 1996](#)). HP is an acute phase response protein that prevents HB-induced toxicity and is induced by inflammatory cytokines ([Levy et al., 2010](#)). Therefore, in both the acute phase and healthy states, TLF2-mediated trypanosome immunity likely predominates. However, TLF1-mediated trypanosome immunity may play a more prominent role when HP levels are low, such as in the case of chronic malaria infection. Malaria infection is associated with sharply decreased plasma HP levels as a result of cyclical hemolysis and subsequent HBHP complex clearance by macrophages, reviewed here ([Rogerson, 2006](#)). Human co-infection with malaria in the context of trypanosome infection is common, as trypanosome endemic regions typically overlap with the distribution of malaria in sub-Saharan Africa ([Onkoba et al., 2015](#)). The estimated 200 million annual cases of malaria could select for an HPHBR-mediated trypanocidal effect in co-infected individuals. To clarify this explicitly, we hypothesize that TLF2 is the main lytic component of normal human serum and that the entry of TLF2 into the parasite is dependent on low-affinity interactions between the TLF2-IgMs and VSG, but that under conditions when circulating HP levels are low, TLF1 uptake will predominate.

Human-infective trypanosomes are resistant to TLF-mediated lysis. *T. b. rhodesiense* parasites express serum resistance associated protein (SRA) that binds to and inhibits the activity of human APOL1 ([Vanhamme et al., 2003](#)), while *T. b. gambiense* uses a combinatorial APOL1 resistance mechanism that is dependent on reduced APOL1 uptake via a mutated HPHBR and the *Trypanosoma gambiense*-specific glycoprotein (TgsGP), which is associated with the inhibition of APOL1 activity ([Uzureau et al., 2013](#)). However, human population studies ([Cooper et al., 2017](#)) and *in vivo* experiments using transgenic mice ([Thomson et al., 2014](#)) have revealed that the relationship between trypanosomes and human APOL1 is complicated. Human variants of APOL1 called G1 and G2 provide increased resistance to human-infective trypanosomes. The G2 variant of APOL1 has a decreased affinity for the SRA protein from *T. b. rhodesiense* ([Thomson et al., 2014](#)), and humans harboring the G2 allele are 5-fold less likely to be infected with *T. b. rhodesiense* parasites ([Cooper et al., 2017](#)). The G1 variant is associated with a 3-fold decreased probability of developing clinical symptoms during *T. b. gambiense* infection ([Cooper et al., 2017](#)), though the mechanism has not been characterized. Importantly, studies have revealed that human TLF can lyse *T. b. gambiense* parasites when TLF1-associated APOL1 uptake is increased by expressing the *T. b. brucei* HPHBR in the absence of HP ([Uzureau et al., 2013](#)). However, HP levels are elevated during trypanosome infections ([Ngure et al., 1997](#)), which prevents TLF1-mediated lytic activity ([Raper et al., 1996](#)). Thus, in individuals infected with African trypanosomes, we hypothesize that TLF2 would be the predominant lytic factor that prevents or controls the infection, and indeed we have observed that *T. b. rhodesiense*-infected humans have markedly increased levels of circulating TLF2 relative to TLF1 ([Figure 5B](#)). We interpret these data as a shift in the TLF1:TLF2 equilibrium toward TLF2 due to an increase in the production of IgM antibodies in response to the trypanosome




Figure 5. Trypanosome Infection Increases TLF2-IgM Production in Sleeping Sickness Patients

Samples were taken from patients infected with *T. b. rhodesiense* before or after treatment with suramin or melarsoprol. For all panels, P values represent Bonferroni-corrected Mann-Whitney U tests: ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.

(A) Plasma IgM levels determined by ELISA (Invitrogen) in sleeping sickness patients compared with control samples from healthy donors (error bars indicate the median and IQR). (B) Determination of the ratio of TLF2-associated APOL1 to TLF1-associated APOL1 by western blot following native agarose gel electrophoresis in sleeping sickness patients compared with control samples from healthy donors (error bars indicate the median and IQR).

(C) Plasma IFN-gamma levels determined by ELISA in sleeping sickness patients compared to control samples from healthy donors (error bars indicate the median and IQR). The American group did not exist at the time that this analysis was performed and are thus not included (see STAR Methods).

(D) Plasma APOL1 levels determined by western blot in sleeping sickness patients compared with control samples from healthy donors (error bars indicate the median and IQR).

(E) Plasma APOA-I levels determined by western blot in sleeping sickness patients compared with control samples from healthy donors (error bars indicate the median and IQR).

infection. Taken together, these data suggest that the balance between trypanosome immunity, control, and active infection is determined by the host's APOL1 genotype and both the rate and ultimately the functional amount of APOL1 taken up by the parasites. We maintain that the field to this day does not have a full understanding of the structure and function of TLFs. Continued investigation of how these HDL complexes and their associated antibodies impact trypanosome immunity is crucial to understanding the relationship between trypanosomes and their primate hosts.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead Contact
 - Materials Availability
 - Data and Code Availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Mice
 - Cell Lines
 - Human Plasma
- METHOD DETAILS
 - Experimental Design
 - TLF2 Detection in AID^{-/-} Mice after HGD
 - TLF2 Detection in Infected and Cured Mice after HGD
 - Purification of Human TLF2 and Murine HDL
 - 24-hour Trypanosome In Vitro Lysis Assay

- Native Agarose Gel Electrophoresis
- Far Western Blotting
- Quantifications of Plasma Proteins in Humans
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.chom.2020.04.012>.

ACKNOWLEDGMENTS

This work was supported by NSF Bread award IOS-1249166 and Hunter College (J.R.); CUNY Science Scholarship (J.V.); Hunter College HHMI UGRAD Science Education grant 52007535 (E.H.); NIH/NIAID award AI085973 (N.P.); Wellcome Trust award 082786 (J.S.). We thank George Cross and Ana Rodriguez for the parasite lines and VSG preparations used in this study.

AUTHOR CONTRIBUTIONS

Conceptualization, J.V., R.Z., and J.R.; Methodology, J.V., R.Z., N.P., and J.R.; Investigation, J.V., R.Z., R.T., S.J.P., N.P., J.S., and J.R.; Writing – Original Draft, J.V., R.Z., and J.R.; Writing – Review & Editing, J.V., R.Z., and J.R.; Funding Acquisition, N.P., J.S., and J.R.; Resources, N.P., J.S., and J.R.; Supervision, J.R.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: February 12, 2019
 Revised: February 20, 2020
 Accepted: April 14, 2020
 Published: May 15, 2020

WEB RESOURCES

Cytiva Life Sciences, <https://www.gelifesciences.com/en/us/solutions/protein-research/knowledge-center/protein-purification-methods/size-exclusion-chromatography#size-exclusion>.

REFERENCES

Baral, T.N., De Baetselier, P., Brombacher, F., and Magez, S. (2007). Control of Trypanosoma evansi infection is IgM mediated and does not require a type I inflammatory response. *J. Infect. Dis.* 195, 1513–1520.

Bullard, W., Kieft, R., Capewell, P., Veitch, N.J., Macleod, A., and Hajduk, S.L. (2012). Haptoglobin-hemoglobin receptor independent killing of African trypanosomes by human serum and trypanosome lytic factors. *Virulence* 3, 72–76.

Cardoso De Almeida, M.L., and Turner, M.J. (1983). The membrane form of variant surface glycoproteins of Trypanosoma brucei. *Nature* 302, 349–352.

Carrington, M., Miller, N., Blum, M., Roditi, I., Wiley, D., and Turner, M. (1991). Variant specific glycoprotein of Trypanosoma brucei consists of two domains each having an independently conserved pattern of cysteine residues. *J. Mol. Biol.* 227, 823–835.

Cooper, A., Ilboudo, H., Alibu, V.P., Ravel, S., Enyaru, J., Weir, W., Noyes, H., Capewell, P., Camara, M., Milet, J., et al. (2017). APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. *eLife* 6, e25461.

Engstler, M., Pfohl, T., Herminghaus, S., Boshart, M., Wiegertjes, G., Heddergott, N., and Overath, P. (2007). Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes. *Cell* 131, 505–515.

Feingold, K.R., and Grunfeld, C. (2000). The effect of inflammation and infection on lipids and lipoproteins. In *Endotext*, L.J. De Groot, G. Chrousos, M. Dungan, K.R. Feingold, A. Grossman, J.M. Hershman, C. Koch, M. Korbonits, R. Mclachlan, and M. New, et al., eds. (Dartmouth Publishing).

Hajduk, S.L., Moore, D.R., Vasudevacharya, J., Siqueira, H., Torri, A.F., Tytler, E.M., and Esko, J.D. (1989). Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. *J. Biol. Chem.* 264, 5210–5217.

Ilboudo, H., Berthier, D., Camara, M., Camara, O., Kabore, J., Leno, M., Keletigui, S., Chantal, I., Jamonneau, V., Belem, A.M., et al. (2012). APOL1 expression is induced by Trypanosoma brucei gambiense infection but is not associated with differential susceptibility to sleeping sickness. *Infect. Genet. Evol.* 12, 1519–1523.

Kovacsics, D., and Raper, J. (2014). Transient expression of proteins by hydrodynamic gene delivery in mice. *J. Vis. Exp.*

Levy, A.P., Asleh, R., Blum, S., Levy, N.S., Miller-Lotan, R., Kalet-Litman, S., Anbinder, Y., Lache, O., Nakhoul, F.M., Asaf, R., et al. (2010). Haptoglobin: basic and clinical aspects. *Antioxid. Redox Signal* 12, 293–304.

Macleod, L., Odiit, M., Macleod, A., Morrison, L., Sweeney, L., Cooper, A., Kennedy, P.G., and Sternberg, J.M. (2007). Spatially and genetically distinct African Trypanosome virulence variants defined by host interferon-gamma response. *J. Infect. Dis.* 196, 1620–1628.

MacLean, L.M., Odiit, M., Chisi, J.E., Kennedy, P.G., and Sternberg, J.M. (2010). Focus-specific clinical profiles in human African trypanosomiasis caused by Trypanosoma brucei rhodesiense. *PLoS Negl. Trop. Dis.* 4, e906.

Molina-Portela, M.P., Samanovic, M., and Raper, J. (2008). Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. *J. Exp. Med.* 205, 1721–1728.

Mugnier, M.R., Cross, G.A., and Papavasiliou, F.N. (2015). The in vivo dynamics of antigenic variation in Trypanosoma brucei. *Science* 347, 1470–1473.

Müller, N., Mansfield, J.M., and Seebeck, T. (1996). Trypanosome variant surface glycoproteins are recognized by self-reactive antibodies in uninfected hosts. *Infect. Immun.* 64, 4593–4597.

Ngure, R.M., David Eckersall, P., Jennings, F.W., Burke, J.M., Stear, M.J., Kennedy, P.G.E., and Murray, M. (1997). Major acute phase response of

haptoglobin and serum amyloid-P following experimental infection of mice with Trypanosoma brucei. *Parasitol. Int.* 46, 247–254.

Onkoba, N.W., Chimbari, M.J., and Mukaratirwa, S. (2015). Malaria endemicity and co-infection with tissue-dwelling parasites in Sub-Saharan Africa: a review. *Infect. Dis. Pover.* 4, 35.

Pinger, J., Nešić, D., Ali, L., Aresta-Branco, F., Lilic, M., Chowdhury, S., Kim, H.S., Verdi, J., Raper, J., Ferguson, M.A.J., et al. (2018). African trypanosomes evade immune clearance by O-glycosylation of the VSG surface coat. *Nat. Microbiol.* 3, 932–938.

Raper, J., Fung, R., Ghiso, J., Nussenzweig, V., and Tomlinson, S. (1999). Characterization of a novel trypanosome lytic factor from human serum. *Infect. Immun.* 67, 1910–1916.

Raper, J., Nussenzweig, V., and Tomlinson, S. (1996). The main lytic factor of Trypanosoma brucei in normal human serum is not high density lipoprotein. *J. Exp. Med.* 183, 1023–1029.

Rifkin, M.R. (1978). Identification of the trypanocidal factor in normal human serum: high density lipoprotein. *Proc. Natl. Acad. Sci. USA* 75, 3450–3454.

Robbiani, D.F., Bothmer, A., Callen, E., Reina-San-Martin, B., Dorsett, Y., Difilippantonio, S., Bolland, D.J., Chen, H.T., Corcoran, A.E., Nussenzweig, A., and Nussenzweig, M.C. (2008). AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. *Cell* 135, 1028–1038.

Rogerson, S. (2006). What is the relationship between haptoglobin, malaria, and anaemia? *PLoS Med* 3, e200.

Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682.

Shimogawa, M.M., Saada, E.A., Vashisht, A.A., Barshop, W.D., Wohlschlegel, J.A., and Hill, K.L. (2015). Cell surface proteomics provides insight into stage-specific remodeling of the host-parasite interface in Trypanosoma brucei. *Mol. Cell. Proteomics* 14, 1977–1988.

Siloși, I., Siloși, C.A., Boldeanu, M.V., Cojocaru, M., Biciușcă, V., Avramescu, C.S., Cojocaru, I.M., Bogdan, M., and Folcuți, R.M. (2016). The role of autoantibodies in health and disease. *Rom. J. Morphol. Embryol.* 57, 633–638.

Stephens, N.A., and Hajduk, S.L. (2011). Endosomal localization of the serum resistance-associated protein in African trypanosomes confers human infectivity. *Eukaryot. Cell* 10, 1023–1033.

Thomson, R., and Finkelstein, A. (2015). Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. *Proc. Natl. Acad. Sci. USA* 112, 2894–2899.

Thomson, R., Genovese, G., Canon, C., Kovacsics, D., Higgins, M.K., Carrington, M., Winkler, C.A., Kopp, J., Rotimi, C., Adeyemo, A., et al. (2014). Evolution of the primate trypanolytic factor APOL1. *Proc. Natl. Acad. Sci. USA* 111, E2130–E2139.

Uzureau, P., Uzureau, S., Lecordier, L., Fontaine, F., Tebabi, P., Homblé, F., Grélard, A., Zhendre, V., Nolan, D.P., Lins, L., et al. (2013). Mechanism of Trypanosoma brucei gambiense resistance to human serum. *Nature* 501, 430–434.

Vanhamme, L., Paturiaux-Hanocq, F., Poelvoorde, P., Nolan, D.P., Lins, L., Van Den Abbeele, J., Pays, A., Tebabi, P., Van Xong, H., Jacquet, A., et al. (2003). Apolipoprotein L-I is the trypanosome lytic factor of human serum. *Nature* 422, 83–87.

Vanhollebeke, B., De Muylder, G., Nielsen, M.J., Pays, A., Tebabi, P., Dieu, M., Raes, M., Moestrup, S.K., and Pays, E. (2008). A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans. *Science* 320, 677–681.

Vanhollebeke, B., Nielsen, M.J., Watanabe, Y., Truc, P., Vanhamme, L., Nakajima, K., Moestrup, S.K., and Pays, E. (2007). Distinct roles of haptoglobin-related protein and apolipoprotein L-I in trypanolysis by human serum. *Proc. Natl. Acad. Sci. USA* 104, 4118–4123.

Vanhollebeke, B., and Pays, E. (2010). The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. *Mol. Microbiol.* 76, 806–814.

Weckerle, A., Snipes, J.A., Cheng, D., Gebre, A.K., Reisz, J.A., Murea, M., Shelness, G.S., Hawkins, G.A., Furdai, C.M., Freedman, B.I., et al. (2016). Characterization of circulating APOL1 protein complexes in African Americans. *J. Lipid Res.* 57, 120–130.

Wu, H., Liu, G., and Shi, M. (2017). Interferon gamma in African trypanosome infections: friends or foes? *Front. Immunol.* 8, 1105.

Wu, Y., Li, Q., and Chen, X.Z. (2007). Detecting protein-protein interactions by Far western blotting. *Nat. Protoc.* 2, 3278–3284.

Zhaorigetu, S., Wan, G., Kaini, R., Jiang, Z., and Hu, C.A. (2008). ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. *Autophagy* 4, 1079–1082.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-human APOL1 (1:10,000)	ProteinTech Group	Cat#16139-1-AP
Anti-human HP/R (1:10,000)	Sigma Aldrich	Cat#H8636
Anti-mouse APOA-I (1:10,000)	Abcam	Cat#Ab20453
Anti-human APOA-I (1:5000)	Novus Biologicals	Cat#NB400-147
Anti-mouse IgM (1:10,000)	Jackson Immuno Research Labs	Cat#115-036-075
Anti-human IgM (1:5000)	Jackson Immuno Research Labs	Cat#09-035-129
Anti-rabbit TrueBlot (1:10,000)	Rockland Antibodies	Cat#18-8813-33
Pooled human IgM	Sigma Aldrich	Cat#I8260
Pooled mouse IgM	Sigma Aldrich	Cat#PP50
Biological Samples		
Ugandan human plasma	See Table 1	N/A
American human plasma	New York University Medical Center	N/A
Chemicals, Peptides, and Recombinant Proteins		
Sodium pyruvate	Thermo Fisher	Cat#MT-25-000-CI
Bathocuprione di-sulfonic acid	Thermo Fisher	Cat#AC164060010
Penicillin/Streptomycin	Thermo Fisher	Cat#15140122
L-cysteine	Sigma Aldrich	Cat#C7352
Hypoxanthine	Sigma Aldrich	Cat#H9636
Thymidine	Sigma Aldrich	Cat#T1895
2-mercaptoethanol	Invitrogen	Cat#21985-023
Fetal bovine serum	Gemini Bio-Products	Cat#S01520; Lot#A95E82G
Serum plus	Sigma Aldrich	Cat#14008C
Iscoves modified DMEM	Laboratory Disposable Products	Cat#10-016-CV
DMEM	Laboratory Disposable Products	Cat#10-017-CM
Diminazene aceturate	Sigma Aldrich	Cat#D7770
Sterile saline	Thermo Fisher	Cat#NC9054335
Experimental Models: Cell lines		
Human HepG2 cells	ATCC	Cat#HB-8065
Human NTera-2 cells	ATCC	Cat#CRL-1973
Trypanosoma brucei Lister-427	Gift from George Cross	N/A
Trypanosoma brucei AnTat 1.1	Gift from George Cross	N/A
Experimental Models: Organisms/Strains		
Mouse A/J	Jackson Laboratories	Cat#000646
Mouse Swiss Webster	Taconic Biosciences	SW Murine Pathogen Free
Mouse AID knockout	Jackson Laboratories	Cat#007770
Recombinant DNA		
pRG977-APOL1/HPR	Molina-Portela et al., 2008 – Vector backbone originally from Regeneron Pharmaceuticals	N/A
pRG977-HPR	Molina-Portela et al., 2008 – Vector backbone originally from Regeneron Pharmaceuticals	N/A
pRG977-APOL1	Molina-Portela et al., 2008 – Vector backbone originally from Regeneron Pharmaceuticals	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Software and Algorithms		
GraphPad Prism	GraphPad software	https://www.graphpad.com/scientific-software/prism/
FIJI	Schindelin et al., 2012	N/A

RESOURCE AVAILABILITY**Lead Contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jayne Raper (raper@genectr.hunter.cuny.edu).

Materials Availability

This study did not generate any unique distributable reagents.

Data and Code Availability

This study did not generate any digitally accessible data or code.

EXPERIMENTAL MODEL AND SUBJECT DETAILS**Mice**

To generate TLFs in mice, we transiently expressed *APOL1* and *HPR* by HGD. The genes of interest were cloned into the pRG977 ([Molina-Portela et al., 2008](#)) mammalian expression vector ([Figures 1A, 2A, and 2D](#)). Each gene of interest is flanked by an intron (5' with respect to the coding sequence) and a polyadenylation signal (3' with respect to the coding sequence) to stabilize the resulting RNA transcripts. The expression of each gene is driven by a mammalian ubiquitin promoter, which functions in any murine cell type. Each plasmid contains a beta-lactamase gene for antibiotic selection and an origin of replication for propagation in *E. coli*. Plasmids are isolated from bacteria such that all contaminating endotoxin is removed (Qiagen). Mice were transfected by HGD as described in ([Kovacsics and Raper, 2014](#)). Briefly, 25 µg of plasmid DNA diluted in approximately 2 to 3 milliliters of saline is then injected directly into the tail vein of an adult mouse (amount of saline is 10% of the weight of the mouse in vol/g). The majority of gene expression in mice receiving plasmids encoding TLF genes by tail vein injection is observed in hepatocytes.

To generate TLF2 in mice that had increased levels of germline IgMs, we used male and female *AID* knockout mice (8-12 weeks old). To generate TLF2 in mice that had been previously infected with trypanosomes, we used female *A/J* mice (6-12 weeks old) and outbred female Swiss Webster mice (6-12 weeks old). Trypanosome infections were carried out by infecting on day 0 with 5000 monomorphic *T. b. brucei* Lister-427 parasites intraperitoneally followed by treatment with 200 µl of 1.25 mg/mL diminazene aceturate on day 4 post-infection. Mice were confirmed parasite free by blood smear on days 5, 6, and 7. For the generation of (anti-trypanosome IgMs) antibodies used in Far western blots, mice were infected with 5000 pleomorphic AnTat 1.1 parasites intraperitoneally and monitored for 12 days before plasma harvest.

All animal experiments were approved by the Institutional Animal Care and Use Committee at Hunter College, which both have currently approved Animal Welfare Assurance Agreements with the National Institutes of Health Office for Protection from Research Risks. 1-4 mice were housed per cage, and the mice were maintained on a 12-hour light cycle.

Cell Lines

The trypanosomes used in the *in vivo* experiments in this study were the Lister-427 and AnTat 1.1 strains of *Trypanosoma brucei*. The Lister-427 line was also grown *in vitro* using HMI-9 media supplemented with 10% FBS, 10% Serum Plus, and penicillin/streptomycin at 37°C with 5% CO₂. The human cell lines used in this study were HepG2 cells (ATCC HB-8065) and NTera-2 cells (ATCC CRL-1973). The human cells were grown in DMEM supplemented with 10% FBS.

Human Plasma

Human African trypanosomiasis patient and control plasma samples were a randomly selected subset of those previously described in ([Maclean et al., 2007](#)). Subjects or their guardians signed consent forms after receiving standard information in their local language. Protocols were approved by the Grampian Research Ethics Committee (Aberdeen) and the Ministry of Health (Uganda). Patient demographics and details of treatment are summarised in [Table 1](#). "Before treatment" samples were taken on admission prior to commencement of treatment. "After treatment" samples were taken as part of the diagnostic confirmation of cure 6 weeks after admission. Staging criteria and treatment regimens were fully described previously in ([MacLean et al., 2010](#)).

METHOD DETAILS

Experimental Design

All experiments were performed without blinding or randomization. All murine-based TLF2 generation experiments were repeated at least once, with representative experiments shown throughout the manuscript. All Far western blots were repeated extensively with reproducible results. All statistical analyses are detailed in “quantification and statistical analysis.”

TLF2 Detection in AID^{-/-} Mice after HGD

Mice were exsanguinated using 200 μ l of heparin (Abraxis) per mouse 24 h after HGD (2 mice per transgenic group; 1 mouse with saline control) and the isolated plasma was pooled (800 μ l per group; 400 μ l for saline group) for immediate size fractionation on a Superose 6 column (1.5 by 60 cm) via Fast Performance Liquid Chromatography (FPLC) (V_0 : 34 mL, flow rate: 0.4 mL/min, fraction size: 500 μ l). Collected fractions were diluted in SDS-PAGE loading buffer and run on 10% tris-glycine gels. Where shown, IgM, APOA-I, and APOL1 were visualized on the same membrane for all groups, while HPR was visualized from a separate membrane. The elution volumes are used in the labeling of the blots, rather than arbitrary fraction numbers, for the purposes of promoting future reproducibility. Fractions containing TLF2 were concentrated to a 500 μ l volume (Centricon – Fisher Scientific) and subjected to co-immunoprecipitation (Co-IP) (APOL1/HPR dual expression: fractions 67 mL and 67.5 mL, HuHPR expression: fractions 65.5 mL – 67.5 mL). Co-immunoprecipitation was performed using magnetic protein A/G beads (Thermo-Pierce). Briefly, antibodies were cross-linked to beads using disuccinimidyl suberate, which were then incubated with protein samples for either 1 h at room temperature or overnight at 4°C. Beads were then washed 5X with tris-buffered saline (TBS) (pH 6.7 in order to increase the stringency of the wash steps and prevent non-specific interactions between the TLFs and the beads) before being boiled in SDS-PAGE gel loading buffer. Antibodies used for Co-IP: Anti-Hu HP mouse monoclonal (Sigma H6396), Mouse IgG1 (Invitrogen 02-6100). All membranes for western blots were blocked using 5% milk in TBS with 0.05% Tween-20.

TLF2 Detection in Infected and Cured Mice after HGD

Swiss Webster and A/J mice were infected on day 0 with 5000 monomorphic *T. b. brucei* Lister-427 parasites I.P. followed by treatment with diminazene aceturate on day 4 post-infection. Mice were transiently transfected with a vector encoding APOL1 and HPR by HGD on day 12 post infection and were subsequently exsanguinated using 200 μ l of heparin (Abraxis) per mouse on day 14 post infection. 400 μ l (to maximize APOL1 yield and achieve detection on western blots) of plasma was immediately loaded onto a Superdex 200 10/300 column and fractionated via FPLC (V_0 : 7 mL, flow rate 1 mL/min, fraction size: 500 μ l). Collected fractions were diluted in SDS-PAGE loading buffer and run on 10% tris-glycine gels.

Purification of Human TLF2 and Murine HDL

TLF2 was purified as described previously with modifications (Raper et al., 1999). Peripheral venous blood from healthy donors in New York (United States) was obtained. Approval was obtained from the institutional review board (IRB) at New York University School of Medicine. Briefly, the density of the isolated plasma (100 mL, HP haplotype 1-1) was adjusted to 1.25 g/mL using KBr. The plasma was then ultracentrifuged at 49,000 RPM, 10°C, 16 h. The bottom 50% of the resulting density gradient was collected and dialyzed using three changes of TBS-2.5 mM EDTA at 4°C. The dialyzed product was concentrated (Centricon – Fisher Scientific) to roughly 40 mL and sized (5 mL per run) on a Superose 6 column (1.5 by 60 cm, V_0 : 34 mL, flow rate: 1.5 mL/min, fraction size: 1.5 mL). Fractions in the TLF2 range were pooled, concentrated to 10 mL, and immunoaffinity purified using a mouse monoclonal antibody raised against human HP that recognizes human HPR (Sigma H6396). The antibody was coupled via amino groups to a HiTrap N-hydroxysuccinimide column as per the manufacturer’s instructions (GE Healthcare Bio-Sciences). The pooled TLF2 was then loaded onto the column and allowed to bind for 10 min, followed by a wash with five column volumes of TBS. The bound TLF2 was then eluted with a 100 mM glycine-150 mM NaCl solution at pH 2.8. Eluted fractions were immediately neutralized with 1.5 M Tris-HCL (pH 8), pooled, and concentrated. The affinity-purified sample was reduced in SDS-PAGE loading buffer containing β -mercaptoethanol and run on 10% polyacrylamide gels for silver staining or transferred to PVDF membranes for immunoblotting. The quality of the purified TLFs is shown in Figure S2.

Murine HDL was prepared using a simplified protocol. One day post-plasmid HGD, mice were sacrificed and exsanguinated. The density of the collected plasma was adjusted to 1.25 g/mL with KBr in 12 mL of TBS and the samples were ultracentrifuged as described above (49,000 RPM, 10°C, 16 h). At this point, the top 33% of the density gradient was collected, dialyzed into TBS, and concentrated. There is no need to separate the HDL from other lipoproteins by density, as the concentration of contaminating LDL is negligible in mice and can be efficiently removed by size fractionation.

24-hour Trypanosome In Vitro Lysis Assay

Cultured *T. b. brucei* Lister-427 parasites were diluted to 5×10^5 mL⁻¹ in HMI-9 medium with 10% fetal calf serum (Laboratory Disposable Products) and 10% Serum Plus (SAFC Biosciences) and 100 μ l was added to each well of an opaque 96 well plate. Parasites were then diluted 1:1 with serially diluted concentrations of purified human TLF2. After 20 h of incubation at 37°C, 20 μ l of alamarBlue (Invitrogen) was added to each well. The assay involves the reduction of resazurin by metabolically active cells to the fluorescent resorufin, allowing quantitation of non-lysed cells at 1-4 h post-reagent addition. Where indicated, the trypanosomes were pre-

treated for 30 min with 10 mM ammonium chloride (which remained present throughout the assay), a weak base that inhibits APOL1-mediated lysis of trypanosomes by neutralizing the endocytic compartments of the organism.

Native Agarose Gel Electrophoresis

0.7% SeaKem agarose (Lonza) was prepared in a running buffer composed of 90 mM Tris and 90 mM borate at pH 8.5. A pigmented Ferritin marker (Pharmacia) that migrates the same distance as the bulk of human HDL was used to determine when to stop gel electrophoresis. Protein samples were prepared via 1:1 dilution in 15% Ficoll 400 buffered with Tris-HCl. A total of 10 μ l of concentrated (10 fold) murine TLF2 fractions or 1.5 μ l of whole human or murine plasma was loaded into the gels and run at a constant voltage of 100V for 2 h. Proteins were transferred to PVDF membranes for western blotting via capillary transfer overnight.

Far Western Blotting

Protein-protein interactions were analyzed by Far western blotting, reviewed here (Wu et al., 2007). SDS-PAGE gels were used to separate proteins by size, which were then transferred to PVDF membranes. Protein samples were reduced with 100 mM β -mercaptoethanol where indicated. Membranes were blocked using 5% BSA in TBS with 0.05% Tween-20. Where indicated, membranes were then probed using 20 μ g/mL of purified human TLF2, or an equimolar amount of pooled human IgM (Sigma, Cat: I8260), in the presence of 5% BSA in TBS with 0.05% Tween-20 for 1 h at room temperature. This was followed by three washes (10 min each) in TBS with 0.05% Tween-20. Membranes were visualized using an anti-Hu IgM polyclonal antibody conjugated to HRP, meaning that any detectable bands would be resolved by the secondary antibody binding to the TLF2-IgM at that particular site. The Far western blot protocol was performed analogously for the dot blot (blot overlay assay) experiments with the following exception: Proteins were not denatured in SDS loading buffer in order to further facilitate the maintenance of native protein structure. Protein samples (2 μ l) were applied directly to a nitrocellulose membrane and allowed to dry for ~15 min prior to probing.

Quantifications of Plasma Proteins in Humans

To quantify IgM, plasma samples were diluted between 10,000 and 100,000-fold prior to being screened in a commercially purchased sandwich ELISA (Invitrogen, biological limit of detection: 15.6 ng/ml).

Plasma interferon (IFN) gamma concentrations were measured using ELISA (BD OptEIA, BD Biosciences, Oxford, UK, biological limit of detection: 1.8 pg/ml). Note that the “before treatment” data are a subset of values previously published in (Maclean et al., 2007) but are included for clarity and for comparison with “after treatment” data. Specifically, the data are reproduced in part from Figure 2A. Lorna MacLean et al. Spatially and Genetically Distinct African Trypanosome Virulence Variants Defined by Host Interferon- γ Response. *The Journal of Infectious Diseases* (2007) 196 (11): 1620-1628. By permission of Oxford University Press on behalf of the Infectious Diseases Society of America, available at: <https://academic.oup.com/jid/article/196/11/1620/1992925?searchresult=1>.

To quantify APOL1, 0.375 μ l of each plasma sample was electrophoresed on 10% polyacrylamide gels alongside a serially diluted sample of purified recombinant APOL1 at a known concentration. The gels were blotted onto PVDF membranes for western blotting and pixel density quantification studies via FIJI (Schindelin et al., 2012). The levels of APOA-I were measured by the same method except that only 10-20 nl of each plasma sample was electrophoresed alongside a serially diluted sample of recombinant APOA-I (Peptotech 350-11).

The ratio of TLF2:TLF1 was calculated by western blot and pixel density quantification via FIJI (Schindelin et al., 2012) after native agarose gel electrophoresis. 1.5 μ l of each plasma sample was electrophoresed for 2 h in 0.7% agarose and blotted onto PVDF membranes. The membranes were probed for the presence of APOL1 which was used to indicate how much of each TLF species was present in each sample. The ratio was determined by comparing the pixel density of the signal corresponding to TLF2-associated APOL1 to TLF1-associated APOL1.

QUANTIFICATION AND STATISTICAL ANALYSIS

Pixel density quantifications were carried out using FIJI (Schindelin et al., 2012). Graphical and statistical analyses were carried out in GraphPad Prism version 7 (GraphPad Software, La Jolla, California, USA). Statistical analyses were only applied to the data in Figure 5. Each data set was initially analyzed by the Kruskal-Wallis test to determine if statistically significant differences existed. If so, we applied individual Mann-Whitney tests to compare differences between groups before performing Bonferroni corrections: **** P <0.0001, *** P <0.001, ** P <0.01, * P <0.05.